



Understanding underreporting of ADR in the Philippines

08 June 2022



About the research

Collaboration:



Title:

“Understanding underreporting of adverse drug reactions in the Philippines”



Special Programme for Research and Training in Tropical Diseases (TDR)

Year proposed: 2019
Year granted: 2021
Grant: USD 50,000

PI: **Mark Ryann A. Lirasan, RPh**
Head, Pharmacovigilance
Food and Drug Administration
Philippines

Co-PI: **Mark Harvey Adamson, RPh**
Dean, School of Pharmacy
Philippine Women's University



Objectives

“Understanding underreporting of adverse drug reactions in the Philippines”

1. Assess the **knowledge**, prevailing **attitudes** and current **practices** on ADR reporting among healthcare professionals at the public health facility level and within public health programs to **understand country-specific factors that may be contributing to ADR reporting**;
2. Assess the **effectiveness of the eReporting** module for Vigiflow among healthcare professionals
3. Assess the **usability of the eReporting module** for Vigiflow among healthcare providers



Study Design

“Understanding underreporting of adverse drug reactions in the Philippines”



quantitative

K A P

qualitative

FGD

eReporting
MODULE FOR VIGIFLOW®




“Understanding underreporting of adverse drug reactions in the Philippines”




Profession
4,347 responses

- Medical Doctor
- Pharmacist
- Nurse
- Others




“Understanding underreporting of adverse drug reactions in the Philippines”

Have you ever reported what you suspected to be an adverse drug reaction (ADR) associated with a medication?




“Understanding underreporting of adverse drug reactions in the Philippines”

If you suspected an adverse event associated with a medication, would you know how to report it?




“Understanding underreporting of adverse drug reactions in the Philippines”

Which of the following is (are) available reporting options (in your workplace) for ADR reporting?



“Understanding underreporting of adverse drug reactions in the Philippines”


If you are going to report a suspected ADR, which of the following methods do you prefer



“Understanding underreporting of adverse drug reactions in the Philippines”


eReporting MODULE FOR VIGIFLOW®

How did you access the e-Reporting link?



On the screen that contains 'Send Report', what was the last word appearing on the UPPER part of screen.


*If you choose the incorrect answer, you...irected to the same link so that you can try again.



“Understanding underreporting of adverse drug reactions in the Philippines”

1. I think I would like to use this eReporting System frequently.

641 responses



FDA eReporting (System Usability Survey)

This is a standard 10-item questionnaire that measures the overall usability of FDA eReporting System. Please select an answer that best expresses how you feel about each statement after using the eReporting System.


1 – Strongly Disagree | 2 – Disagree | 3 – Neutral | 4 – Agree | 5 – Strongly Agree



“Understanding underreporting of adverse drug reactions in the Philippines”

2. I found the eReporting System unnecessarily complex.

641 responses



FDA eReporting (System Usability Survey)

This is a standard 10-item questionnaire that measures the overall usability of FDA eReporting System. Please select an answer that best expresses how you feel about each statement after using the eReporting System.


1 – Strongly Disagree | 2 – Disagree | 3 – Neutral | 4 – Agree | 5 – Strongly Agree



“Understanding underreporting of adverse drug reactions in the Philippines”

3. I thought the eReporting System was easy to use.

641 responses



FDA eReporting (System Usability Survey)

This is a standard 10-item questionnaire that measures the overall usability of FDA eReporting System. Please select an answer that best expresses how you feel about each statement after using the eReporting System.


1 – Strongly Disagree | 2 – Disagree | 3 – Neutral | 4 – Agree | 5 – Strongly Agree



“Understanding underreporting of adverse drug reactions in the Philippines”

4. I think that I would need the support of a technical person to be able to use this eReporting System.


641 responses



“Understanding underreporting of adverse drug reactions in the Philippines”

5. I found the various functions in this eReporting System were well integrated.

641 responses



FDA eReporting (System Usability Survey)

This is a standard 10-item questionnaire that measures the overall usability of FDA eReporting System. Please select an answer that best expresses how you feel about each statement after using the eReporting System.


1 – Strongly Disagree | 2 – Disagree | 3 – Neutral | 4 – Agree | 5 – Strongly Agree



“Understanding underreporting of adverse drug reactions in the Philippines”

6. I thought there was too much inconsistency in this eReporting System.

641 responses



FDA eReporting (System Usability Survey)

This is a standard 10-item questionnaire that measures the overall usability of FDA eReporting System. Please select an answer that best expresses how you feel about each statement after using the eReporting System.


1 – Strongly Disagree | 2 – Disagree | 3 – Neutral | 4 – Agree | 5 – Strongly Agree



“Understanding underreporting of adverse drug reactions in the Philippines”

7. I would imagine that most people would learn to use this eReporting System very quickly

641 responses



FDA eReporting (System Usability Survey)

This is a standard 10-item questionnaire that measures the overall usability of FDA eReporting System. Please select an answer that best expresses how you feel about each statement after using the eReporting System.


1 – Strongly Disagree | 2 – Disagree | 3 – Neutral | 4 – Agree | 5 – Strongly Agree



“Understanding underreporting of adverse drug reactions in the Philippines”

8. I found the eReporting System very awkward to use.

641 responses



FDA eReporting (System Usability Survey)

This is a standard 10-item questionnaire that measures the overall usability of FDA eReporting System. Please select an answer that best expresses how you feel about each statement after using the eReporting System.


1 – Strongly Disagree | 2 – Disagree | 3 – Neutral | 4 – Agree | 5 – Strongly Agree



“Understanding underreporting of adverse drug reactions in the Philippines”

9. I felt very confident using the eReporting System.

641 responses



FDA eReporting (System Usability Survey)

This is a standard 10-item questionnaire that measures the overall usability of FDA eReporting System. Please select an answer that best expresses how you feel about each statement after using the eReporting System.


1 – Strongly Disagree | 2 – Disagree | 3 – Neutral | 4 – Agree | 5 – Strongly Agree



“Understanding underreporting of adverse drug reactions in the Philippines”

10. I needed to learn a lot of things before I could get going with this eReporting System.

641 responses



“Understanding underreporting of adverse drug reactions in the Philippines”

Ongoing: Focused Group Discussions

Expected end of research: before end of 2022

Publication: 2022-2023

“Understanding underreporting of adverse drug reactions in the Philippines”

Future directions...

- 1. Identify Gaps**
- 2. Create and implement interventions**
- 3. Evaluate intervention**
- 4. Propose further development**

 **END**

THANK YOU!



www.fda.gov.ph



info@fda.gov.ph



FDA 
Food and Drug Administration
PHILIPPINES